This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Clinical trial NCT07321860 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07321860
- Sponsor
- Gipfel Life Sciences GmbH
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-30
- Primary completion
- 2027-06-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.